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Background. Empirical antibiotic therapy for nongonococcal urethritis (NGU) and cervicitis is aimed at Chla-
mydia trachomatis, butMycoplasma genitalium, which also commonly causes undiagnosed NGU, necessitates treat-
ment with macrolides or ﬂuoroquinolones rather than doxycycline, the preferred chlamydia treatment. Prevalence
of M. genitalium and associated genotypic markers of macrolide and ﬂuoroquinolone resistance among men symp-
tomatic of urethritis were investigated. Genetic diversity of M. genitalium populations was determined to infer
whether ﬁndings were applicable beyond our setting.
Methods. Mycoplasma genitalium and other NGU pathogens were detected using nucleic acid ampliﬁcation
methods, and DNA sequencing was used to detect genotypic resistance markers of macrolide and ﬂuoroquinolone
antibiotics in 23S ribosomal RNA, gyrA, gyrB, and parC genes. MG191 single-nucleotide polymorphism typing and
MG309 variable number tandem analysis were combined to assign a dual locus sequence type (DLST) to each posi-
tive sample.
Results. Among 217 men, M. genitalium prevalence was 16.7% (95% conﬁdence interval [CI], 9.5%–24.0%)
and C. trachomatis prevalence was 14.7% (95% CI, 7.8%–21.6%) in NGU cases. Nine of 22 (41%; 95% CI, 20%–
62%) patients withM. genitalium were infected with DLSTs possessing genotypic macrolide resistance and 1 patient
was infected with a DLST having genotypic ﬂuoroquinolone resistance. Typing assigned M. genitalium DLSTs to 2
major clusters, broadly distributed among previously typed international strains. Genotypic macrolide resistance
was spread within these 2 clusters.
Conclusions. Mycoplasma genitalium is a frequent undiagnosed cause of NGU in this population with rates of
macrolide resistance higher than those previously documented. Current guidelines for routine testing and empirical
treatment of NGU should be modiﬁed to reduce treatment failure of NGU and the development of further resistance.
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Mycoplasma genitalium and Chlamydia trachomatis
are recognized causes of common genital tract
morbidities, such as pelvic inﬂammatory disease and
nongonococcal cervicitis in women [1] and nongono-
coccal urethritis (NGU) in men [2, 3]. UK- and US-
based antimicrobial treatment guidelines for these
syndromes are aimed at Chlamydia infection, which is
more frequently detected and has a strong evidence
base for causing chronic disease [4, 5], whereasM. geni-
talium is not usually recommended among organisms
for routine testing in routine sexually transmitted infec-
tion screening. NGU, diagnosed using both clinical
presentation with Gram-stained urethral smear micros-
copy, is empirically treated with a 1-week oral course of
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doxycycline or a single oral dose of 1 g of azithromycin [4, 5].
Both are effective against C. trachomatis, although clinical
failure to eradicate Chlamydia with single-dose azithromycin
has been reported [6]. For M. genitalium, doxycycline has poor
efﬁcacy, evidenced by high rates of clinical failure with tetracy-
clines [7]; treatment failure with single-dose azithromycin is
increasingly evident and associated worldwide with strains pos-
sessing single-nucleotide polymorphisms (SNPs) in its ribosom-
al RNA gene (domain V, 23S rRNA) [8–10]. Moxiﬂoxacin, a
ﬂuoroquinolone demonstrating efﬁcacy against M. genitalium, is
recommended following treatment failure with macrolides and
tetracyclines [1]. Fluoroquinolone resistance–associated SNPs in
gyrase (gyrA) or topoisomerase IV (parC) genes have been de-
tected inM. genitalium from patients exhibiting ﬂuoroquinolone
treatment failure and phenotypic resistance in vitro [11].
In this study of men symptomatic of urethritis, we investigat-
ed the prevalence of M. genitalium in comparison to estab-
lished causes of urethritis and determined frequencies of
known genetic resistance markers to macrolides and ﬂuoro-
quinolones within M. genitalium. We sought to establish
whether prevalence of M. genitalium and resistance was local
only to our population or could be applicable more generally,
using a previously validated dual-locus typing system.
METHODS
Patients
This was an observational study of all men prospectively pre-
senting with symptoms of urethritis to the Genitourinary Med-
icine Clinic at St George’s Hospital, Tooting, London, between
28 September and 15 December 2011. This study was conduct-
ed with the approval of the South West London Research
Ethics Committee (number Q0803 71). Patients were designat-
ed as having urethritis, NGU, nonchlamydial NGU, or no ure-
thritis. “Urethritis” was deﬁned as any patient receiving
treatment speciﬁcally for urethritis in that clinical episode and
at least 1 of the following: (1) recent history of dysuria, urethral
discomfort, or urethral discharge, and visible urethral discharge
on examination; (2) ≥5 neutrophils per high-power ﬁeld on
urethral Gram stain. NGU was deﬁned as urethritis where gon-
orrhea was excluded by at least 2 of Gram stain, nucleic acid
ampliﬁcation test (NAAT), and routine gonococcal culture.
Nonchlamydial NGU was deﬁned as NGU where chlamydia
had been excluded by NAAT. Only patients consenting to
routine urethral smears were included in the study. Patients
had a urethral smear prepared with a cotton-tipped swab or
plastic loop and were asked to provide a maximum of 50 mL
ﬁrst-catch urine specimen. Clinical notes of patients with ure-
thritis were reviewed at 3 months after presentation to assess
instances of treatment failure.
Pathogen Detection
First-void urine samples were collected routinely for chlamydia
and gonorrhea NAATs using the Viper system (Becton Dickin-
son, Oxford, UK). The residual of these samples were retrieved
and used for detection of M. genitalium and T. vaginalis using
primers as previously described [12, 13]. DNA extracts positive
forM. genitalium were investigated for SNPs in the quinolone re-
sistance–determining regions (QRDRs) of gyrA, gyrB, and parC
and macrolide resistance SNPs in 23S rRNA [8] and also typed
using a multiple locus variable number tandem repeat marker in
MG309 (MG-309-STR) and mgpB SNP analysis [14]. Further
details of the protocol are provided in Supplementary Data 1.
Statistical Analysis
To detect the difference of 25% and 4% of M. genitalium in pa-
tients with and without urethritis, respectively [1], with 80% power
and α = .05, 111 urethritis and nonurethritis cases each were re-
quired. Prevalence of infections was compared between urethritis
and no urethritis and also compared within urethritis cases for
the same infection, using χ2 andMcNemar test, respectively.
Sequence Type Assignment and Phylogeny Construction
MG191 sequence type (ST) type was assigned on the basis of pre-
viously described types [15–17] numbered 1–80. Maximum like-
lihood phylogeny was reconstructed from ClustalW alignments
using RAxML v7.3.2 using a generalized time reversible (GTR)
model of nucleotide substitution with gamma model of rate het-
erogeneity [18]. Branch support values were generated from 1000
bootstrap replicates.
RESULTS
Prevalence of Infection
217 men were recruited, 18 of whom were men who have sex
with men (MSM). One hundred ten of 217 had any urethritis
by study deﬁnition and 102 of 217 had NGU. The prevalence of
C. trachomatis and M. genitalium were similar in NGU cases
and both signiﬁcantly higher than in those with no urethritis
(Table 1). The prevalence of both M. genitalium and C. tracho-
matis among MSM and heterosexual men with NGU was
similar (data not shown). The clinic database was checked for
all male attendees during the exact period of the study. Of 184
men diagnosed with NGU, 14 were diagnosed with C. tracho-
matis, giving a prevalence of 7.6% (95% conﬁdence interval
[CI], 4.4%–12.7%), lower than in our study. This may have re-
ﬂected a different threshold for diagnosing NGU in the general
clinic compared to our study criteria.
Genotypic Resistance Markers
Genotypic resistance data were available for both the macrolide
and ﬂuoroquinolone antibiotics for all 22 M. genitalium–
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positive clinical samples (Table 2). Macrolide resistance was de-
tected in 9 samples (41%; [95% CI, 20%–62%]). A single
sample, that is, 4.5% (95% CI, 1%–21%), possessed a mutation
in the QRDR of parC associated with ﬂuoroquinolone resis-
tance, and this genotype possessed no genotypic resistance
markers of macrolide antibiotics. The parC sequence of the
isolate containing a SNP within the QRDR and the sequences
of domain V of the 23S rRNA gene have been deposited within
GenBank under the nucleotide accession numbers HF947096
and HF572928–HF572950, respectively.
There were no obvious clinical associations with antibiotic
resistance. Macrolide-associated resistance markers were
carried in 6 of 17 and 3 of 5 of those with NGU and no urethri-
tis, respectively.
In 1 of these patients, carrying A2058G, the clinical notes in-
dicated reception of single-dose azithromycin for a prior
episode of NGU some months previously, raising the possibili-
ty of either treatment failure or selection of macrolide resistance
from the previous episode. However, none of the 6 cases with
NGU and macrolide resistance, 2 of whom were treated with
doxycycline and 4 with single-dose azithromycin, returned to
the clinic in the following 6 months with episodes of persistent
or recurrent urethritis.
Relatedness ofM. genitalium
All 22 M. genitalium DNAs were successfully sequence typed
by the MG191 SNP typing system. Eighteen of 22 were success-
fully typed using MG-309-STR. Table 2 displays MG191
(mgpB) and MG-309-STR types together with 23S rRNA type.
Eleven of 22 M. genitalium infections were caused by 8 STs
identical to MG191 alleles in the literature [14–16], designated
ST 2, 3, 4, 8, 21, 23, 24, and 44. The remaining 11 sequence
types exhibited novel MG191 alleles which we have designated
as Novel STs A–J (Table 2). Sequences used for typing were de-
posited in GenBank under accession numbers KC445139 to
KC445161 for the mgpB locus and KC445162 to KC445182 for
theMG309 locus.
Successfully typed MG-309-STR sequences were combined
end-to-end with their respective MG191 sequences to form a
dual locus sequence type (DLST). Phylogenetic analysis revealed
a tree of 18 DLSTs, divided clearly into 2 major clusters, which
we designated Major Cluster A (MCA) and B (MCB) (Figure 1).
A phylogenetic tree, constructed using only MG191 sequences on
study sequence types, produced identical assignments into these
major clusters with poorer bootstrap values (data not shown). We
therefore assigned the 4 sequence types, in which MG-309-STR
had failed, to these major clusters accordingly (Table 2). Seven of
12 MCA types exhibited genotypic resistant mutations (4
A2058G, 2 A2059G, and 1 A2059C), compared with 2 of 10 in
MCB (A2058G and A2059G) (Table 2 and Figure 1). We deter-
mined the phylogenetic relationship of study M. genitalium STs
with 80 other previously typed strains [15–18] from Southern
Europe and North Africa, which were typed using MG191-ST
alone (Supplementary Figure). The tree suggests that our study
M. genitalium STs, including those carrying 23S rRNA mutants,
are distributed widely in this group of STs.
DISCUSSION
Mycoplasma genitalium was a frequent but undiagnosed cause
of NGU, as prevalent as C. trachomatis in our symptomatic,
mainly heterosexual male cohort. In addition, >40% ofM. geni-
talium infections had genotypic resistance to macrolide antibi-
otics, one of the recommended ﬁrst-line options for NGU. A
Table 1. Prevalence of Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma genitalium, and Trichomonas vaginalis for No
Urethritis, Gonococcal Urethritis, Nongonococcal Urethritis (NGU), and Nonchlamydial NGU
Organism
No
Urethritis All Urethritis
P Valuea for
All Urethritis
Nongonococcal
Urethritis (NGU)
P Valuea
for NGU NCNGU
P Valuea for
NCNGU
Neisseria gonorrhoeae 2/107; 1.9%
(.0–4.5)
7/109; 6.4%
(1.8–11.0)
.17 NA . . . NA . . .
Chlamydia trachomatis 2/107; 1.9%
(.0–4.5)
17/109; 15.6%
(10.0–24.0)
.0001 15/102; 14.7%
(7.8–21.6)
.0007 NA . . .
Mycoplasma genitalium 5/107; 4.7%
(.7–8.7)
17/110; 15.5%
(8.7–22.3)
.0085 17/102; 16.7%
(9.5–24.0)
.0047 17/87; 19.5%
(11.2–27.8)
.0012
Trichomonas vaginalis 0/107
0%
2/110;1.8%
(0–4.3)
.49 2/102; 2.0%
(0–4.7)
.24 2/87; 2.3%
(0%–5.0%)
.46
P value, Ct vs Mgb 1 .86
Data in parentheses represent the 95% confidence intervals.
Abbreviations: Ct, Chlamydia trachomatis; Mg, Mycoplasma genitalium; NA, not applicable; NCNGU, nonchlamydial nongonococcal urethritis; NGU,
nongonococcal urethritis.
a P values represent comparisons with no urethritis.
b P values are for comparisons between C. trachomatis andM. genitalium prevalence.
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single patient, approximately 5% of the cohort, was infected
with a strain demonstrating genotypic resistance to ﬂuoroquin-
olones. Patients with M. genitalium infection, with or without
genotypic resistance, separated into distinct genotypic clusters
and were also related to a diverse population of international
control sequence types. This indicated that our ﬁndings, rather
than being a local clonal phenomenon that could have biased
the data, were more likely to represent established infection and
resistance rates in this patient population as a whole.
This also complements evidence that selection of macrolide-
resistant M. genitalium during suboptimal treatment [19] con-
tributes to cases of treatment failure rather than ongoing hori-
zontal transmission of resistant bacterial strains. Overall, our
ﬁndings indicate that there is a need to provide routine testing
for M. genitalium in those presenting with symptoms of ure-
thritis and perhaps cervicitis and that ﬁrst-line recommended
antimicrobial options for treating these syndromes need reap-
praisal [20, 21].
Table 2. Clinical, Demographic, and Genotypic Characteristics of Patients WithMycoplasma genitalium Infection
ID
Sexual
Orientation Diagnosis Treatment
Antibiotics
in Last
6 mo
Follow-
up
mgpB
SNP
Typea
MG309 vntr
Copy
Number
23S rRNA
Mutation
Mutant
Fluoroquinolone
QRDR: Amino
Acid Changeb
Major
Cluster
mgpBc
Major
Cluster
Dualc
170 MSW NGU Doxycycline ND Nil A 15 A2058G WT A A
202 MSW NGU Doxycycline ND ND 44 Nontypeable A2059C WT A
11 MSW Nil Nil ND 1 wkd 3 9 WT WT A A
227 MSW Nil Nil ND 1 moe 3 11 A2059G WT A A
107 MSW NGU Azithromycin
1 g
ND 5 mof E 15 WT parC:
S83R (80)
A A
141 MSW NGU Azithromycin
1 g
ND Nil 4 9 A2058G WT A A
184 MSW Nil Nil ND Nil J 8 A2059G WT A A
183 MSW Nil Nil Ceftriaxone Nil 4 10 A2058G WT A A
219 MSW NGU-
HSV
Doxycycline ND Nil I 10 WT WT A
189 MSW NGU Doxycycline None Nil H Nontypeable WT WT A
43 MSW NGU Doxycycline ND Nil 3 15 A2058G WT A A
22 MSW NGU Doxycycline Doxycycline 1 mog B 13 WT WT A
174 MSM NGU Doxycycline None Nil G 13 WT WT B B
162 MSW NGU Doxycycline ND Nil C 14 WT WT B B
197 MSW NGU Azithromycin
1 g
Azithromycin
1 g
Nil 24 10 A2058G WT B B
51 MSW NGU Doxycycline ND 2 moh C 13 WT WT B B
108 MSW NGU Azithromycin
1 g
ND Nil 8 9 WT WT B B
111 MSW NGU Doxycycline ND Nil F 9 WT WT B B
218 MSW NGU Doxycycline ND 6 wki 23 19 WT WT B B
88 MSW NGU Azithromycin
1 g
ND Nil 21 8 A2059G WT B B
116 MSW Nil Nil ND Nil 2 11 WT WT B B
72 MSW NGU Doxycycline ND Nil D 10 WT WT B B
Abbreviations: HSV, herpes simplex virus; MSW, men who have sex with women; ND, not documented; NGU, nongonococcal urethritis; Nil, no follow-up
attendance; QRDR, quinolone resistance–determining region; rRNA, ribosomal RNA; SNP, single-nucleotide polymorphism; WT, wild type.
a Sources: [8, 14, 15].
b Parentheses represent the codon of Escherichia coli K12.
c BothmgpB and dual sequence type phylogenetic analysis produced the same two major clusters as presented in Figure 1.
d Persistent symptoms; doxycycline given.
e Urethral discharge, nil found.
f Chlamydia trachomatis diagnosed–asymptomatic.
g Persistent symptoms; azithromycin (2 g) given over 5 days.
h Persistent symptoms for 2 months; azithromycin (2 g) over 5 days and metronidazole given.
i Persistent symptoms; doxycycline and metronidazole given.
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These treatment options will need to take into account the
need to have effective regimens against both C. trachomatis and
M. genitalium and should question the value of recommending
either doxycycline or single-dose azithromycin alone. Whereas
extended-dose azithromycin for NGU may be more effective in
preventing the development of macrolide resistance and treat-
ment failure, the in vitro and clinical data suggest that it will
not work for those carrying 23s rRNA resistance-associated
SNPs [19]. Future effective NGU regimens are likely to include
ﬂuoroquinolones. Solitary parC mutations, like the one docu-
mented in this study, have been reported in cases of ﬂuoroquin-
olone treatment failure of M. genitalium [22, 23], and
worryingly, there already exist reports of moxiﬂoxacin treat-
ment failure in M. genitalium–associated persistent NGU [24].
Collectively, these ﬁndings point to the need to evaluate effec-
tiveness of new treatment strategies, including combination
therapies and novel antimicrobials.
Effective management can be further guided by providing
routine testing for M. genitalium infection [25], and tests of
cure following therapy. The prospect of rapid and accurate tests
for infections that include validated genetic markers of resis-
tance [26, 27] will allow for appropriately targeted treatment
and reduce need for complex regimens. Current rapid test plat-
forms in development, including those recently approved for C.
trachomatis and Neisseria gonorrhoeae, offer potential for such
resistance tests to be realized [28].
The prevalence of M. genitalium in NGU in our study was
perhaps at the lower end of the range of that described in previ-
ous work of 15%–25% [3]. Recent reports in South Africa mirror
our ﬁndings of higher rates ofM. genitalium infection relative to
C. trachomatis [29], and importantly, comparable rates of macro-
lide resistance and emerging evidence of resistance to resistance
to ﬂuoroquinolones were reported in Sydney, Australia [30], sug-
gesting that the problem may be globally widespread.
Although this study is limited by being based in a single
clinic as well as conducted over a relatively short period of time,
we addressed this by assessing the genetic diversity of M. geni-
talium within our cohort, utilizing a typing system with the dis-
criminatory power to be useful in the study of sexual networks
[14]. This robustly revealed 2 major clusters of M. genitalium,
Figure 1. Phylogenetic tree of 18 of 22 dual locus sequence types of Mycoplasma genitalium detected from symptomatic men attending clinic. The tree
was constructed only from samples in which both MgpB and MG309 sequences were available using the mgpB sequence type combined with MG309 vntr
sequence (dual locus sequence type). Tips are colored by 23S rRNA single-nucleotide polymorphism type. Branch tips show identity number followed by
the abbreviations ST, mgpB sequence type; vntr, MG309 sequence type repeat, and clinical syndrome; NGU, nongonococcal urethritis; Nil, no clinical syn-
drome. POS indicates positive control. The numbers along the branches represent bootstrap values. Major clusters A and B (see text).
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both of which contained drug-resistant mutations. Each cluster
itself contained different MG191 STs, many of which had been
previously identiﬁed. The MG191 typing system alone is less
discriminatory and more useful to describe broad epidemiolog-
ical STs [14]. Using this system, we showed that most STs
within each cluster were not closely related as they were distrib-
uted broadly among international genotypes also typed using
MG191.
In conclusion, the prevalence of macrolide-resistant M. geni-
talium in this population is much higher than previously
thought and M. genitalium is detected as frequently as C. tra-
chomatis in cases of NGU. Current testing and treatment
guidelines should be modiﬁed to incorporate these ﬁndings.
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